343603-82-7

Usage

Uses

Used in Flavoring Industry:
2-Methoxy-4-phenylbenzaldehyde is used as a flavoring agent for its distinctive sweet and aromatic properties, enhancing the taste and aroma of foods, beverages, and pharmaceuticals.
Used in Antioxidant Applications:
In the field of food preservation and health supplements, 2-Methoxy-4-phenylbenzaldehyde is utilized as an antioxidant to prevent the oxidation of fats and oils, thereby extending the shelf life of products and maintaining their quality.
Used in Antimicrobial Applications:
2-Methoxy-4-phenylbenzaldehyde is employed as an antimicrobial agent in various industries, including food and pharmaceuticals, to inhibit the growth of bacteria and other microorganisms, ensuring product safety and efficacy.
Used in Aromatherapy:
In the aromatherapy industry, 2-Methoxy-4-phenylbenzaldehyde is used for its calming and soothing effects, helping to reduce stress and promote relaxation.
Used in Perfumery:
In the perfumery industry, 2-Methoxy-4-phenylbenzaldehyde is used as a fixative to enhance the longevity and intensity of fragrances, providing a pleasant and lasting scent.
Used in Cosmetics:
2-Methoxy-4-phenylbenzaldehyde is used in the cosmetics industry for its pleasant aroma and potential skin conditioning properties, contributing to the overall sensory experience and effectiveness of skincare products.

Upstream product

• 156001-73-9 trifluoromethanesulfonic acid 4-formyl-3-methoxyphenyl ester 
• 98-80-6 phenylboronic acid 
• 591-51-5 phenyllithium 
• 43192-33-2 4-bromo-2-methoxybenzaldehyde 
• 18278-34-7 4-hydroxy-2-methoxybenzaldehyde 
• 2113-56-6 3-methoxybiphenyl 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 175153-18-1 3-(methyloxy)-4-biphenylcarboxylic acid 
• 35664-67-6 3-hydroxy-[1,1'-biphenyl]-4-carbaldehyde 

Relevant academic research and scientific papers

Synthesis of Substituted Benzaldehydes via a Two-Step, One-Pot Reduction/Cross-Coupling Procedure

The synthesis of functionalized (benz)aldehydes, via a two-step, one-pot procedure, is presented. The method employs a stable aluminum hemiaminal as a tetrahedral intermediate, protecting a latent aldehyde, making it suitable for subsequent cross-coupling with (strong nucleophilic) organometallic reagents, leading to a variety of alkyl and aryl substituted benzaldehydes. This very fast methodology also facilitates the effective synthesis of a 11C radiolabeled aldehyde. Aluminum-ate complexes enable transmetalation of alkyl fragments onto palladium and subsequent cross-coupling.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

Synthesis of novel structurally simplified estrogen analogues with electron-donating groups in ring A

A library of 25 novel estrogen analogues were prepared in five to eight steps from mostly commercially available substituted anisoles via bromination, formylation, Corey-Fuchs reaction, elimination, and Sonogashira reaction. Georg Thieme Verlag Stuttgart.

Purinenucleoside derivative modified in 8-position and medical use thereof

The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF

The present invention providesbenzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory activity on sodium-dependent nucleoside transporter 2 and are useful for a disease associated with an abnormality of plasma uric acid level. The compounds of the present invention are useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R1 and R2 are H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; R3 is H, a halogen atom, optionally substituted alkyl group or the like; R9 and R5 are H, a halogen atom, OH or the like; and R6 and RX are H or OH: RY is F or OH.

1-[2-methoxy-5-(3-phenylpropyl)]-2-aminopropane unexpectedly shows 5-HT2A serotonin receptor affinity and antagonist character

Certain phenylethylamines, such as 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB; 1a), are high-affinity 5-HT2 agonists. Previous structure - affinity studies have concluded that both the 2,5-dimethoxy substitution pattern and the nature of substituents at the 4-position are important determinants of high affinity. We recently demonstrated that replacement of the bromo group of DOB with a 3-(phenyl)propyl substituent results in retention of affinity and that, counter to established structure - affinity relationships, the 2,5-dimethoxy substitution pattern is no longer a requirement for the binding. The present investigation extends these findings by examining a series of analogues, 3, lacking a 5-methoxy group. It was additionally found that shifting the phenylalkyl substituent from the 4- to the 5-position (e.g., 4i) also results in retention of affinity. For example, 1-(2-methoxy-5-(3-phenylpropyl)-2-aminopropane (6; the α-methyl derivative of 4i) binds at 5-HT2A receptors with high affinity (Ki = 13 nM) and possesses 5-HT2A antagonist character. Thus, not only is the 2,5-dimethoxy substitution pattern not a requirement for the binding of certain phenylethylamines at 5-HT2A receptors, the presence of a 4-position substituent (previously thought to serve as a modulator of affinity of DOB-like agents) is also not required. Striking differences in the 5-HT2A binding requirements of the present compounds as compared to DOB-like agents suggest multiple substituent-dependent modes of binding.